PL343373A1 - Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily - Google Patents
Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamilyInfo
- Publication number
- PL343373A1 PL343373A1 PL99343373A PL34337399A PL343373A1 PL 343373 A1 PL343373 A1 PL 343373A1 PL 99343373 A PL99343373 A PL 99343373A PL 34337399 A PL34337399 A PL 34337399A PL 343373 A1 PL343373 A1 PL 343373A1
- Authority
- PL
- Poland
- Prior art keywords
- inhibition
- treatment
- cysteine proteases
- parasitic diseases
- papain superfamily
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8122198P | 1998-04-09 | 1998-04-09 | |
PCT/US1999/007723 WO1999053039A1 (en) | 1998-04-09 | 1999-04-08 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily |
Publications (1)
Publication Number | Publication Date |
---|---|
PL343373A1 true PL343373A1 (en) | 2001-08-13 |
Family
ID=22162839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL99343373A PL343373A1 (en) | 1998-04-09 | 1999-04-08 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1068304A4 (es) |
JP (1) | JP2002511491A (es) |
KR (1) | KR20010042535A (es) |
CN (1) | CN1304447A (es) |
AR (1) | AR020065A1 (es) |
AU (1) | AU3482099A (es) |
CA (1) | CA2327282A1 (es) |
CO (1) | CO5080800A1 (es) |
DZ (1) | DZ2752A1 (es) |
HU (1) | HUP0101513A2 (es) |
IL (1) | IL138628A0 (es) |
MA (1) | MA26618A1 (es) |
NO (1) | NO20005032L (es) |
PE (1) | PE20000421A1 (es) |
PL (1) | PL343373A1 (es) |
TR (1) | TR200002940T2 (es) |
WO (1) | WO1999053039A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143742A (en) * | 1997-12-11 | 2000-11-07 | Fuisz Technologies Ltd | Treatment for necrotizing infections |
DZ2796A1 (fr) * | 1998-05-21 | 2003-12-01 | Smithkline Beecham Corp | Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
EP1143951A3 (en) | 1998-09-21 | 2002-02-06 | University Of Florida Research Foundation, Inc. | Antimalarial agents |
EP1488791A3 (en) * | 1998-09-21 | 2005-04-06 | University Of Florida Research Foundation, Inc. | Antimalarial agents |
CO5150165A1 (es) * | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | Inhibidores de proteasa: tipo catepsina k |
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034599A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
US6583137B1 (en) | 1999-11-10 | 2003-06-24 | Smithkline Beecham Corporation | Protease inhibitors |
JP2003513924A (ja) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
CN1416346A (zh) | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
US6635784B2 (en) | 2000-09-29 | 2003-10-21 | Eastman Chemical Company | Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates |
ES2261341T3 (es) * | 2000-11-17 | 2006-11-16 | Medivir Ab | Inhibidor de cisteina proteasa. |
MXPA03006224A (es) | 2001-01-17 | 2004-10-15 | Amura Therapeutics Ltd | Inhibidores de cruzipaina y otras proteasas de cisteina. |
US7132449B2 (en) | 2001-01-17 | 2006-11-07 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
IL156776A0 (en) | 2001-01-17 | 2004-02-08 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases |
EP1465862A1 (en) | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
WO2005034949A1 (en) | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
TR201910900T4 (tr) | 2005-04-04 | 2019-08-21 | Univ Florida | Desferritiyokin polieter analogları. |
WO2007012180A1 (en) * | 2005-07-26 | 2007-02-01 | Merck Frosst Canada Ltd. | Papain family cysteine protease inhibitors for the treatment of parasitic diseases |
NZ579994A (en) | 2007-03-15 | 2011-09-30 | Univ Florida | Desferrithiocin polyether analogues useful in the treatment of pathological conditions responsive to chelation or sequestration of trivalent metal |
EP2225196B1 (en) | 2007-11-29 | 2015-01-28 | Merck Canada Inc. | Cysteine protease inhibitors for the treatment of parasitic diseases |
WO2009087379A2 (en) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases |
MX368275B (es) | 2011-12-16 | 2019-09-26 | Univ Florida | Usos de análogos de 4'-desferritiocina. |
EP2633855A1 (en) | 2012-03-01 | 2013-09-04 | Veterinärmedizinische Universität Wien | Protease inhibitors for treating Trichomonas gallinae infections |
JP6838966B2 (ja) | 2013-11-22 | 2021-03-03 | ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. | デスフェリチオシン類似体およびその使用 |
KR20170140306A (ko) | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
CZ132798A3 (cs) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
DZ2285A1 (fr) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
MA26487A1 (fr) * | 1997-04-29 | 2004-12-20 | Smithkline Beecham Corp | Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant . |
-
1999
- 1999-04-05 MA MA25522A patent/MA26618A1/fr unknown
- 1999-04-07 AR ARP990101578A patent/AR020065A1/es unknown
- 1999-04-07 DZ DZ990053A patent/DZ2752A1/xx active
- 1999-04-08 CO CO99020595A patent/CO5080800A1/es unknown
- 1999-04-08 PL PL99343373A patent/PL343373A1/xx not_active Application Discontinuation
- 1999-04-08 WO PCT/US1999/007723 patent/WO1999053039A1/en not_active Application Discontinuation
- 1999-04-08 EP EP99916517A patent/EP1068304A4/en not_active Withdrawn
- 1999-04-08 HU HU0101513A patent/HUP0101513A2/hu unknown
- 1999-04-08 CN CN99807012A patent/CN1304447A/zh active Pending
- 1999-04-08 IL IL13862899A patent/IL138628A0/xx unknown
- 1999-04-08 TR TR2000/02940T patent/TR200002940T2/xx unknown
- 1999-04-08 KR KR1020007011178A patent/KR20010042535A/ko not_active Application Discontinuation
- 1999-04-08 CA CA002327282A patent/CA2327282A1/en not_active Abandoned
- 1999-04-08 AU AU34820/99A patent/AU3482099A/en not_active Abandoned
- 1999-04-08 JP JP2000543587A patent/JP2002511491A/ja not_active Withdrawn
- 1999-04-09 PE PE1999000290A patent/PE20000421A1/es not_active Application Discontinuation
-
2000
- 2000-10-06 NO NO20005032A patent/NO20005032L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2327282A1 (en) | 1999-10-21 |
NO20005032D0 (no) | 2000-10-06 |
EP1068304A1 (en) | 2001-01-17 |
IL138628A0 (en) | 2001-10-31 |
JP2002511491A (ja) | 2002-04-16 |
CO5080800A1 (es) | 2001-09-25 |
AR020065A1 (es) | 2002-04-10 |
MA26618A1 (fr) | 2004-12-20 |
HUP0101513A2 (hu) | 2001-08-28 |
NO20005032L (no) | 2000-11-16 |
EP1068304A4 (en) | 2001-05-09 |
AU3482099A (en) | 1999-11-01 |
CN1304447A (zh) | 2001-07-18 |
TR200002940T2 (tr) | 2001-02-21 |
DZ2752A1 (fr) | 2003-09-15 |
PE20000421A1 (es) | 2000-05-21 |
KR20010042535A (ko) | 2001-05-25 |
WO1999053039A1 (en) | 1999-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL343373A1 (en) | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | |
ATE269866T1 (de) | Intranasale zubereitungen zur behandlung sexueller störungen | |
ID30062A (id) | Alanog-analog benzopiran tersubstitusi untuk pengobatan radang | |
IL160295A0 (en) | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | |
IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
AU4256801A (en) | Treatment of movement disorders | |
IL160065A0 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
HK1070008A1 (en) | Combination of cytochome p 450 dependent protease inhibitors | |
HUP0400024A2 (hu) | Neoplasztikus betegségek kezelésére szolgáló gyógyszerkombinációk | |
ZA9811629B (en) | The use of MMP inhibitors for the treatment of ocular angiogenesis. | |
ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis | |
AU2001278488A1 (en) | Regulation of human matriptase-like serine protease | |
EP1411985A4 (en) | TREATMENT OF PARASITICAL DISEASES | |
AU8573401A (en) | Regulation of human epithin-like serine protease | |
AU2001281967A1 (en) | Regulation of human desc1-like serine protease | |
GB0101146D0 (en) | Treatment of skin conditions | |
AU2002354698A1 (en) | Use of xaa-pro peptidases for the treatment of substance p-related disorders | |
GB0201025D0 (en) | The treatment of degenerative diseases | |
AU2001266089A1 (en) | Regulation of human prostasin-like serine protease | |
GB0100092D0 (en) | Treatment of degenerative diseases | |
AU2001269095A1 (en) | Regulation of human caspase-1-like protease | |
AU2001274446A1 (en) | Vip-related peptides for the treatment of skin disorders | |
AU2001268967A1 (en) | Regulation of human epithin-like serine protease | |
MXPA01010541A (es) | Cisteina proteasa e hinibidores para la prevencion y el tratamiento de la neurocisticercosis. | |
AU2001256350A1 (en) | Regulation of human lysostaphin-like protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |